Pancreatic Cancer Research

ResearcherZhongda Hospital Southeast UniversityActive in the last 2 years

Haodong Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-6865-3928; OpenAlex author ID A5103110058, A5137211723. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Lactylation-related prognostic signature characterized in pancreatic ductal adenocarcinoma through public scRNA-seq dataset and machine learning algorithms: th… Co-author DOI 10.1038/s41416-026-03477-z↗
  2. CAFs-derived LAM332 promotes CTCs formation and survival via ITGA3 and contributes to the metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-026-08642-z↗
  3. TGFBI promotes EMT and perineural invasion of pancreatic cancer via PI3K/AKT pathway. Co-author DOI 10.1007/s12032-025-02736-y↗
  4. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jgm.3570↗
  5. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/tox.23881↗
  6. Identification of Transcriptomic Signatures of Pancreatic Ductal Adenocarcinoma-Derived Exosomes That Promote Macrophage M2 Polarization and Predict Prognosis:… First author DOI 10.1177/11795549241239042↗
  7. Integrated bioinformatics analysis shows integrin alpha 3 is a prognostic biomarker for pancreatic cancer. Co-author DOI 10.1515/med-2022-0606↗
  8. The Crosstalk Between Immune Infiltration, Circulating Tumor Cells, and Metastasis in Pancreatic Cancer: Identification of HMGB3 From a Multiple Omics Analysis. Co-author DOI 10.3389/fgene.2022.892177↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiahua Zhou · 5 shared papers, 2022–2024 · strength 1.12
  2. Siyuan Tan · 3 shared papers, 2024 · strength 0.78
  3. Haifeng Li · 3 shared papers, 2024 · strength 0.78
  4. Jiahua Zhou · 2 shared papers, 2025–2026 · strength 0.55
  5. Hao Ye · 2 shared papers, 2022–2024 · strength 0.40
  6. Peng Ping Xie · 1 shared paper, 2024 · strength 0.28
  7. Peng Xie · 1 shared paper, 2024 · strength 0.28
  8. Fangfang Hu · 1 shared paper, 2026 · strength 0.28
  9. Pengcheng Zhou · 1 shared paper, 2026 · strength 0.28
  10. Wenxing Zhao · 1 shared paper, 2026 · strength 0.27
  11. Tonglei Xu · 1 shared paper, 2025 · strength 0.27
  12. Zeqian Yu · 1 shared paper, 2025 · strength 0.27
  13. Zheng Zhang · 1 shared paper, 2025 · strength 0.27
  14. Fangfang Hu · 1 shared paper, 2022 · strength 0.19
  15. Zheng Zhang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.